

Todd Perkinson Appointed as Chief Financial Officer

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (**Rhythm** or the **Company**) is pleased to announce the appointment of Mr Todd Perkinson as Chief Financial Officer (CFO) effective today, 18th March 2025.

Mr Perkinson brings a wealth of experience in executive leadership, financial management and business transformation. With a proven track record across various industries, Todd has successfully led major mergers and acquisitions, optimised operational efficiency and driven significant revenue growth.

Most recently, at AdNeo Limited (ASX: AD1), Todd spearheaded a business turnaround, delivering multi-million-dollar improvements of EBITDA and NPAT year-over-year. Under Todd's leadership, the company secured a multi-million-dollar capital raise, completed the acquisition of Oliver Grace and expanded its U.S. mentoring subsidiary by over 200%. Prior to this, Todd played a pivotal role in the \$100 million sale of Vault Intelligence to Damstra Holdings, where he oversaw cost reductions, revenue growth and strategic partnerships across the APAC region. In addition to his corporate leadership, Todd has demonstrated exceptional strategic foresight in driving business transformations and process improvements at organisations including Emerge Aotearoa, Nimble Money and Royal District Nursing Service.

A Chartered Accountant with a Bachelor of Commerce and Administration from Victoria University of Wellington, Todd brings a strong analytical and results-driven approach to every role.

Rhythm Managing Director and Chief Executive Officer, Dr David Atkins commented "we are delighted to attract someone of Todd's calibre, broad experience and drive at a time where Rhythm is preparing for significant global growth."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

E investors@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.